Data for Rivaroxaban presented at the 2009 ASH Annual Meeting

December 5 - 8, 2009
New Orleans, Louisiana, USA

Findings from the Phase III EINSTEIN-Extension study have been presented in the Late Breaking Abstract Session on December 8, 2009 at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.

On this occasion we held a conference call for investors and analysts.

Tuesday, December 8, 2009:
Investor Conference Call on Rivaroxaban


Dr. Kemal Malik, Head of Global Development Bayer Schering Pharma
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular and Coagulation, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations

MP3 audio recording (presentation and discussion)

Background Information
About Xarelto®Download (PDF, 2 MB) collect
About EINSTEIN StudiesDownload (PDF, 2 MB) collect
Rivaroxaban Clinical Trial ProgramDownload (PDF, 2 MB) collect
Rivaroxaban BibliographyDownload (PDF, 2 MB) collect
About Venous Thromboembolism (VTE)Download (PDF, 3 MB) collect
GlossaryDownload (PDF, 2 MB) collect

Last updated: January 07, 2014 Copyright © Bayer AG